Viatris Inc. (MYL.VI)
| Previous close | 13.42 |
| Open | 13.42 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 13.42 - 13.42 |
| 52-week range | 8.19 - 13.42 |
| Volume | |
| Avg. volume | 61 |
| Market cap | 7.395B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 26.01 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Viatris to Report First Quarter 2024 Financial Results on May 9, 2024
Viatris Inc. (NASDAQ: VTRS) will report its first quarter 2024 financial results on Thursday, May 9, 2024, before the open of the U.S. financial markets. Chief Executive Officer Scott A. Smith and other Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results.
- PR Newswire
Viatris Appoints Corinne Le Goff as Chief Commercial Officer
Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that Corinne Le Goff has joined the company as Chief Commercial Officer and will become a member of the company's Executive Leadership Team, effective today.
- GlobeNewswire
Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
FARMINGTON HILLS, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of unmet needs of patients with retinal and refractive eye disorders, today announced the U.S. commercial launch of RYZUMVI™ (phentolamine ophthalmic solution) by its partner Viatris Inc. (NASDAQ: VTRS). Ocuphire has a global license agreement with Viatris to co-develop and commercialize Phentolamine O
